|
1
|
Yu XY, Wang Y, Zhong H, Dou QL, Song YL
and Wen H: Diagnostic value of serum procalcitonin in solid organ
transplant recipients: A systematic review and meta-analysis.
Transplant Proc. 46:26–32. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bhatti AB and Usman M: Chronic renal
transplant rejection and possible anti-proliferative drug targets.
Cureus. 7:e3762015.PubMed/NCBI
|
|
3
|
Kreis HA and Ponticelli C: Causes of late
renal allograft loss: Chronic allograft dysfunction, death, and
other factors. Transplantation. 71 (Suppl 11):SS5–SS9.
2001.PubMed/NCBI
|
|
4
|
van Ree RM, de Vries AP, Oterdoom LH,
Seelen MA, Gansevoort RT, Schouten JP, Struck J, Navis G, Gans RO,
van der Heide JJ, et al: Plasma procalcitonin is an independent
predictor of graft failure late after renal transplantation.
Transplantation. 88:279–287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sager R, Kutz A, Mueller B and Schuetz P:
Procalcitonin-guided diagnosis and antibiotic stewardship
revisited. BMC Med. 15:152017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dumea R, Siriopol D, Hogas S, Mititiuc I
and Covic A: Procalcitonin: Diagnostic value in systemic infections
in chronic kidney disease or renal transplant patients. Int Urol
Nephrol. 46:461–468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grace E and Turner RM: Use of
procalcitonin in patients with various degrees of chronic kidney
disease including renal replacement therapy. Clin Infect Dis.
59:1761–1767. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun Y, Jiang L and Shao X: Predictive
value of procalcitonin for diagnosis of infections in patients with
chronic kidney disease: A comparison with traditional inflammatory
markers C-reactive protein, white blood cell count, and neutrophil
percentage. Int Urol Nephrol. 49:2205–2216. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kidney Disease: Improving Global Outcomes
(KDIGO) Transplant Work Group: KDIGO clinical practice guideline
for the care of kidney transplant recipients. Am J Transplant. 9
(Suppl 3):S1–S155. 2009. View Article : Google Scholar
|
|
10
|
National Kidney Foundation, . K/DOQI
clinical practice guidelines for chronic kidney disease:
Evaluation, classification, and stratification. Am J kidney Dis. 39
(2 Suppl 1):S1–S266. 2002.PubMed/NCBI
|
|
11
|
Kaplan B: Overcoming barriers to long-term
graft survival. Am J Kidney Dis. 47 (4 Suppl 2):S52–S64. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen PD, Tsai MK, Lee CY, Yang CY, Hu RH,
Lee PH and Lai HS: Gender differences in renal transplant graft
survival. J Formos Med Assoc. 112:783–788. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Grosso G, Corona D, Mistretta A, Zerbo D,
Sinagra N, Giaquinta A, Caglià P, Amodeo C, Leonardi A, Gula R, et
al: The role of obesity in kidney transplantation outcome.
Transplant Proc. 44:1864–1868. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Papalia T, Greco R, Lofaro D, Maestripieri
S, Mancuso D and Bonofiglio R: Impact of body mass index on graft
loss in normal and overweight patients: Retrospective analysis of
206 renal transplants. Clin Transplant. 24:E241–E246. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Molnar MZ, Czira ME, Rudas A, Ujszaszi A,
Lindner A, Fornadi K, Kiss I, Remport A, Novak M, Kennedy SH, et
al: Association of the malnutrition-inflammation score with
clinical outcomes in kidney transplant recipients. Am J Kidney Dis.
58:101–108. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vazquez MA, Jeyarajah DR, Kielar ML and Lu
CY: Long-term outcomes of renal transplantation: A result of the
original endowment of the donor kidney and the inflammatory
response to both alloantigens and injury. Curr Opin Nephrol
Hypertens. 9:643–648. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Becker KL, Nylén ES, White JC, Müller B
and Snider RH Jr: Clinical review 167: Procalcitonin and the
calcitonin gene family of peptides in inflammation, infection, and
sepsis: A journey from calcitonin back to its precursors. J Clin
Endocrinol Metab. 89:1512–1525. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Becker KL, Snider R and Nylen ES:
Procalcitonin assay in systemic inflammation, infection, and
sepsis: Clinical utility and limitations. Crit Care Med.
36:941–952. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wahn F, Daniel V, Kronenberg F, Opelz G,
Michalk DV and Querfeld U: Impact of apolipoprotein(a) phenotypes
on long-term renal transplant survival. J Am Soc Nephrol.
12:1052–1058. 2001.PubMed/NCBI
|
|
20
|
Kronenberg F: Human genetics and the
causal role of lipoprotein(a) for various diseases. Cardiovasc
Drugs Ther. 30:87–100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Florens N, Calzada C, Lyasko E, Juillard L
and Soulage CO: Modified lipids and lipoproteins in chronic kidney
disease: A new class of uremic toxins. Toxins (Basel). 8:E3762016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kronenberg F: Causes and consequences of
lipoprotein(a) abnormalities in kidney disease. Clin Exp Nephrol.
18:234–237. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Barter P: Lipoprotein metabolism and CKD:
Overview. Clin Exp Nephrol. 18:243–246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Catena C, Colussi G, Nait F, Pezzutto F,
Martinis F and Sechi LA: Early renal failure as a cardiovascular
disease: Focus on lipoprotein(a) and prothrombotic state. World J
Nephrol. 4:374–378. 2015. View Article : Google Scholar : PubMed/NCBI
|
